Sexual Medicine Society of North America, Inc.

FDA announced a Public Advisory Committee Meeting to review the approval of flibanserin for hypoactive sexual desire disorder (HSDD) in women on June 4, 2015

FDA announced a Public Advisory Committee Meeting to review the approval of flibanserin for hypoactive sexual desire disorder (HSDD) in women on June 4, 2015. Should you wish to submit your written comments or request time at the public microphone, the deadline is a week away. Please find all details in the Federal Register Notice by clicking on this link.

Our Services

About SMSNA

Established in 1994, our objective has been to promote, encourage, and support the highest standards of practice, research, education, and ethics in the study of the anatomy, physiology, pathophysiology, diagnosis, and treatment...

~ Read More

Contact Us

SMSNA Executive Office
c/o Status Plus
+1 (952) 683 1917
+1 (952) 314 8212
info@smsna.org

Address
14305 Southcross Dr
Suite 100
Burnsville, MN 55306